Can a Two-Drug combo tame a rare and aggressive gynecologic cancer?
NCT ID NCT05619913
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This phase II trial is testing whether the chemotherapy drug eribulin, given alone or combined with the immunotherapy pembrolizumab, can help people with ovarian or uterine carcinosarcoma that has returned or progressed. The study aims to see if these treatments can shrink tumors or keep them stable for at least 12 weeks. It also looks at whether a protein called HMGA2 can predict who might benefit from the treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eribulin mesylate (Halaven) and pembrolizumab (Keytruda)
- What this could lead to
- If successful, this could offer a new treatment option for people with recurrent ovarian or uterine carcinosarcoma, a rare and aggressive cancer with few options.
- What could go wrong
- This is a small, early-phase study, so results may not be conclusive. The combination may not improve outcomes and could cause side effects like fatigue, nerve damage, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Imperial College London
London, London, United Kingdom
-
Monash Health
Clayton, Victoria, Australia
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 8006, Australia
-
Prince of Wales Hospital
Randwick, New South Wales, Australia
-
Princess Margaret Hospital
Toronto, Ontario, Canada
-
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital therapy aims to tame the fear that haunts cancer survivors
- New combo therapy aims to control ovarian cancer and reduce painful fluid buildup
- New drug cocktail shows promise for Tough-to-Treat uterine cancer
- Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
- New drug combo shows promise for Hard-to-Treat cancers
- New hope for aggressive uterine cancer: targeted drug trial shows promise